Covaxin neutralises double mutant strain
Indigenously developed Covid-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said yesterday.
Bharat Biotech’s Covaxin has received Emergency Use Authorisations (EUAs) for Covid-19 treatment in India and in several countries across the globe with another 60 in the process.
“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR tweeted.
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant) and B.1.351 (South Africa variant).